Domov › Rak hipofarinksa › Virginia
Klinične študije za Rak hipofarinksa v Virginia
5 študij za Rak hipofarinksa išče udeležence na lokacijah v Virginia.
Mesta v Virginia
Uradno besedilo študije (angleško)
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06589804BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Inova Alexandria Hospital, Alexandria
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- in še 6
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05136196Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
- VCU Massey Comprehensive Cancer Center, Richmond
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT05172245Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Community Memorial Health Center, South Hill
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT02734537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT06532279Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.